Skip to main navigation Skip to search Skip to main content

Molecular characterization of mucopolysaccharidosis type IVA patients in the Andean region of Colombia

  • Harry Pachajoa
  • , Maria Amparo Acosta
  • , Carlos J. Alméciga-Díaz
  • , Yoseth Ariza
  • , Lorena Diaz-Ordoñez
  • , Gabriela Caicedo-Herrera
  • , Daniel Cuartas
  • , Jose Antonio Nastasi-Catanese
  • , Diana Ramírez-Montaño
  • , Yiseth Katherine Silva
  • , Lina Moreno
  • , Jose Satizabal
  • , Natalia Garcia
  • , Jorge Montoya
  • , Carlos Prada
  • , Gloria Porras
  • , Harvy Velasco
  • , Estephania Candelo
  • Universidad ICESI
  • Fundación Valle del Lili
  • Universidad del Cauca
  • Universidad del Valle
  • Universidad de Manizales
  • Hospital Universitario San Vicente Fundación
  • Cincinnati Children's Hospital Medical Center
  • University of Cincinnati
  • Fundación Cardiovascular de Colombia
  • INCERHC Centro de investigación Salud Comfamiliar
  • Medical Diagnosis Tools

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Colombia has a high prevalence of mucopolysaccharidosis (MPS) type IVA. Nevertheless, data regarding the mutation spectrum for MPS IVA in this population have not been completely characterized. Forty-seven families and 53 patients from seven different Colombian regions were tested for MPS IVA mutations. We compared the sequences with the N-acetylgalactosamine-6-sulfatase (GALNS) reference sequence NM_000512.4, and gene variants were reported. Bioinformatics analysis was performed using SWISS-MODEL. The mutant proteins were generated by homology from the wild-type GALNS 4FDJ template obtained from the PDB database, and visualization was performed using Swiss-PDBViewer and UCSF Chimera. The predictive analysis was run using different bioinformatic tools, and the deleterious annotation of genetic variants was performed using a neural network. We found that 79% and 21% of the cohort was homozygous and compound heterozygous, respectively. The most frequent mutation observed was p.Gly301Cys (78.3% of alleles), followed by p.Arg386Cys (10.4% of alleles). A novel mutation (p.Phe72Ile) was described and classified in silico as a pathogenic variant. This study reveals the mutation spectrum of MPS IVA in Colombia. The high prevalence of the p.Gly301Cys mutation suggests a founder effect of this variant in the Colombian population that causes diseases in the Andean region (via migration). These data can facilitate genetic counseling, prenatal diagnosis, and the design of therapeutic interventions.

Original languageEnglish
Pages (from-to)388-395
Number of pages8
JournalAmerican Journal of Medical Genetics, Part C: Seminars in Medical Genetics
Volume187
Issue number3
DOIs
StatePublished - Sep 2021

Keywords

  • Colombia
  • MPS IVA
  • Morquio syndrome
  • founder effects
  • mucopolysaccharidosis IV

Fingerprint

Dive into the research topics of 'Molecular characterization of mucopolysaccharidosis type IVA patients in the Andean region of Colombia'. Together they form a unique fingerprint.

Cite this